Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

J&J Remediates Two OTC Facilities To FDA Approval, Waits On Third

This article was originally published in The Tan Sheet

Executive Summary

Its headquarters plant was closed and production at two other facilities was slowed under a 2011 consent decree. J&J did not say when it expects FDA’s decision on the third plant.

Advertisement

Related Content

Missing CAPA Costs J&J $25 Million In Investigation Sparked By OTC Recalls

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register